Du är här


CELYAD S.A.: Celyad participating in Large and Midcap Event in Paris

Mont-Saint-Guibert, Belgium
- Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the
discovery and development of engineered cell therapies, announces its
participation in the 15th edition of the European Large&Midcap Event, which
will be held in Paris this coming October 7th and 8th.

By participating in this event focusing especially on European midcap
companies, Celyad is seizing the opportunity to share its strategy and
present its main development programmes to European institutional
investors and analysts.

Patrick Jeanmart, Administrative and Financial Director of Celyad, comments:
"We are delighted to be participating once again in the Large and Midcap
Event. For two years, Celyad has been developing firm ties with European
institutional investors. This event is ideal for sharing with them the major
advances our company has achieved in recent months in our cardiology and
oncology programmes".


| For more information, please contact: |
| For Europe : Consilium Strategic Communications |
| |
|Amber Fennell, Chris Gardner, Chris Welsh, and Laura Thornton - T: +44 (0)20 |
|3709 5700 -celyad@consilium-comms.com |
| For the U.S. : The Ruth Group |
| |
|Lee Roth (Investors), and Kirsten Thomas (Media) - T: +1 646 536 7012 / 7014 |
|-celyad@theruthgroup.com |
| For France : NewCap |
| |
|Pierre Laurent and Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 |
|-celyad@newcap.fr |
| Celyad |
| |
|Christian Homsy, CEO and Patrick Jeanmart, Chief Financial Officer : T: +32 |
|(0)10 39 41 00 -investors@celyad.com |
| To subscribe to Celyad's newsletter, visit |
|www.celyad.com |
| |
|Follow us on Twitter@CelyadSA |
About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell
therapy with clinical programs initially targeting indications in cardiology
and oncology. Celyad is developing its lead cardiovascular disease product
candidate, C- Cure®, for the treatment of ischemic heart failure, and has
completed enrollment of a Phase III trial in Europe and Israel. In addition,
the Company is developing a novel portfolio of CAR T-cell therapies that
utilize human Natural Killer cell receptors for the treatment of numerous
blood and solid cancers. Its lead oncology product candidate, NKG2D CAR
T-cell, entered a Phase I clinical trial in April 2015.

Celyad's ordinary shares are listed on Euronext Brussels and Euronext Paris
under the ticker symbol CYAD and Celyad's American Depositary Shares are
listed on the NASDAQ Global Market under the ticker symbol CYAD.

To learn more about Celyad, please visitwww.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press
release contains forward-looking statements, including statements about the
safety and efficacy of Celyad's product candidates, the potential clinical
and commercial potential of these product candidates and the adequacy of
Celyad's financial resources, which reflect our current expectations and
projections about future events, and involve certain known and unknown risks,
uncertainties and assumptions that could cause actual results or events to
differ materially from those expressed or implied by the forward- looking
statements. These forward-looking statements are further qualified by
important factors, which could cause actual results to differ materially from
those in the forward-looking statements, including risks associated with
conducting clinical trials; the risk that DSMB's determination not to
discontinue the Phase III clinical trials for C-Cure® on the basis of non-
futility is not a determination as to the likelihood of success and is not a
guarantee that the trial will be successful; the risk that safety,
bioactivity and efficacy demonstrated in earlier clinical or pre-clinical
studies may not be replicated in subsequent studies; risk associated with the
timely submission and approval of anticipated regulatory filings; the
successful initiation and completion of clinical trials, including Phase III
clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-cell;
risks associated with the satisfaction of regulatory and other requirements;
risks associated with the actions of regulatory bodies and other governmental
authorities; risks associated with obtaining, maintaining and protecting
intellectual property, our ability to enforce our patents against infringers
and defend our patent portfolio against challenges from third parties; risks
associated with competition from others developing products for similar uses;
risks associated with our ability to manage operating expenses;, and risks
associated with our ability to obtain additional funding to support our
business activities and establish and maintain strategic business alliances
and business initiatives. A further list and description of these risks,
uncertainties and other risks can be found in the Company's Securities and
Exchange Commission filings and reports, including in the Company's
prospectus filed with the SEC on June 19, 2015 and future filings and reports
by the Company. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. The
Company expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which
any such statement is based, unless required by law or regulation.

C3BS-CQR-1, C-Cure, NKG2D CAR T-cell, C-Cathez, OnCyte, Celyad, Cardio3
BioSciences and the Cardio3 BioSciences, Celyad, C-Cathez, CHART-1, CHART-2
and OnCyte logos are signs internationally protected under applicable
Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of
intellectual property licensed to the Company.

Press release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CELYAD S.A. via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.